FMP
Nuvectis Pharma, Inc.
NVCT
NASDAQ
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
6.5 USD
-0.01 (-0.154%)
About
ceo
Mr. Ron Bentsur M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.nuvectis.com
exchange
NASDAQ
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
CIK
0001875558
ISIN
US67080T1088
CUSIP
67080T108
Address
1 Bridge Plaza
Phone
201 614 3150
Country
US
Employee
13
IPO Date
Feb 4, 2022
Summary
CIK
0001875558
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
67080T108
ISIN
US67080T1088
Country
US
Price
6.5
Beta
0.27
Volume Avg.
93.92k
Market Cap
115.5M
Shares
-
52-Week
6.2-18.65
DCF
1.23
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.55
P/B
-
Website
https://www.nuvectis.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NVCT News
It looks like there's no news available.
